NCT04674722View on ClinicalTrials.gov

HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain Antibody

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

August 24, 2020

Primary Completion Date

May 8, 2024

Study Completion Date

October 30, 2024

Conditions
Breast CancerRadiotoxicity
Interventions
DRUG

Injection of 99mTc-NM-02

A Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer

DRUG

Injection of 188Re-NM-02

A Patient will be injected with microdose (\<100ug) of 188Re-NM-02 radionuclide therapy

Trial Locations (1)

200080

Shanghai General Hospital, Shanghai

All Listed Sponsors
collaborator

NanoMab Technology (UK) Limited

INDUSTRY

lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT04674722 - HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain Antibody | Biotech Hunter | Biotech Hunter